Investment Banking & Brokerage

Analysts at JP Morgan downgraded Impax Laboratories Inc (NASDAQ: IPXL) from “overweight” to “neutral.” IPXL's shares closed at $23.49 yesterday. IPXL's PEG ratio is 1.12. Analysts at Jefferies & Company downgraded SunPower Corporation (NASDAQ: SPWRA) from “buy” to “hold.” SPWRA 's shares...

KBW is out with its report today on Jefferies Group (NYSE: JEF), lowering its PT to $28. In a note to clients, KBW writes, "Lowering 2Q11 est. to $0.40 from $0.43 on a higher share count from the equity capital raise in early April that increased our estimates for the avg. diluted share count by...

Goldman Sachs has upgraded Raymond James (NYSE: RJF) and Knight Capital (NYSE: KCG) to Buy, and has downgraded CBOE Holdings (NASDAQ: CBOE) to Sell. Goldman Sachs has also downgraded Stifel Financial (NYSE: SF) from Buy to Neutral.

Investment Technology Group, Inc. (NYSE: ITG) today announced that it has acquired Ross Smith Energy Group Ltd. a Calgary-based independent provider of research on the oil and gas industry. Going forward, RSEG will be rebranded as ITG Investment Research and the research offering will be an...

Shares of The Charles Schwab Corporation (NASDAQ: SCHW) are lower on the session by 0.18%, currently trading at $16.33. The stock has been moving largely lower over the past four months and is currently trading below the 200-day moving average. Options traders are buying puts on the name today. A...

The markets are floating slightly higher today as the Dollar has fallen sharply once again. Federal Reserve Chairman Ben Bernanke is set to speak at 3:35pm ET today. Knowing this, gave Wall Street a good idea that the markets would most likely see weakness in the Dollar and an up market. The...

Goldman Sachs Group Inc.(NYSE: GS) has been one of the weakest stocks in the stock market as of late. The stock topped out in mid-January 2011 at $175.43 a share and has been steadily declining. The stock is trading below its daily chart 20, 50, and 200 moving averages which put the stock in a...

LaBranche & Co (NYSE: LAB) today issued the following letter to stockholders recommending that they vote FOR the adoption of the merger agreement with Cowen Group (NASDAQ: COWN) at LaBranche's upcoming Special Meeting of Stockholders to be held on June 15, 2011 at the Down Town Association, 60...

The large major banks are leading the major stock market indexes lower for a fourth consecutive trading session. It is important to remember that the four largest banks and many of the leading brokerage firms have been under pressure since the start of May 2011. These stocks are all short term...

Goldman Sachs (NYSE: GS) is going to fight against a Senate report that is damaging the firm's reputation. Portugal's incoming Social Democratic prime minister said he would put together a coalition to make sure the country's austerity measures stay on track. Greek Prime Minister George...

The Goldman Sachs Group, Inc. (NYSE: GS) today announced that it has agreed to sell Litton Loan Servicing to Ocwen Financial Corporation (NYSE: OCN) for approximately $264 million. The sale price does not reflect certain assets that Goldman Sachs will retain. Goldman Sachs does not expect the...

This is your Benzinga news summary and trader's outlook for Monday, June 6, 2011, covering headlines from the weekend and Monday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are still trading slightly lower after Friday's disappointing employment data. The U.S....

Oppenheimer commented on Incyte (NASDAQ: INCY) in a report released today. In the report, Oppenheimer was positive in its assessment of the company. Oppenheimer writes, "On 6/4, INCY/NVS reported final COMFORT-1/2 ph.III data for INCB18424 in myelofibrosis (MF). Notably, the companies reported '...

According to a recent report, Keefe, Bruyette & Woods has updated Stifel Financial (NYSE: SF) from an Outperform rating to a Market Perform rating and has lowered the price target to $47.00. In the report, Keefe, Bruyette & Woods said, "We are upgrading Stifel Financial to Outperform from...

Acorda Therapeutics (Nasdaq: ACOR) today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the...